Peripheral biomarkers in glioblastoma patients—is it all just HOTAIR?

Glioblastoma multiforme is the most aggressive form of brain cancer. The standard of care treatment for newly diagnosed patients with glioblastoma is tumour de-bulking by surgery, followed combination therapy consisting of radiation and temozolomide chemotherapy (1). The tumour invariably recur, often in the same area or adjacent to as the original surgical-resected tumor (2,3).